Avadel Pharmaceuticals plc (AVDL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

6.85

-0.29

(-4.06%)

As of 03:03PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	7.14
Open	7.30
Bid	6.79 x 1000
Ask	6.81 x 800
Day's Range	6.58 - 7.33
52 Week Range	1.05 - 11.59
Volume	698,009
Avg. Volume	4,087,914

Market Cap	409.585M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-1.54
Earnings Date	Aug 09, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	10.95

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AVDL

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Avadel Pharmaceuticals plc
Analyst Report: Jazz Pharmaceuticals plcJazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Rating
Fair Value
Economic Moat
29 days agoMorningstar

All

GlobeNewswire
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Received tentative approval for LUMRYZ™ (sodium oxybate) extended-release for oral suspension from FDA on July 18Advancing key activities to potentially accelerate final approval and shorten launch window of LUMRYZExtended cash runway to final FDA decisionManagement to host a conference call today at 8:00 a.m. ET DUBLIN, Ireland, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today pro
- ClearSign Technologies Corporation Announces Second Quarter 2022 Conference Call
  PR Newswire
- Luna Innovations Reports Second-Quarter 2022 Results
  Business Wire
Zacks
Wall Street Analysts Think Avadel (AVDL) Could Surge 106%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 105.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GlobeNewswire
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9
DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, August 9, 2022, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2022. To access the conference call, investors are invited to dial (833) 630-0586 (U.S.) or (412) 3